Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-CAPNETZ)
Recruiting
- Conditions
- Coronavirus Disease 19 (COVID-19)U07.1J12J13J14J15J16J17J18COVID-19, virus identified
- Registration Number
- DRKS00022871
- Lead Sponsor
- CAPNETZ STIFTUNG, Geschäftsstelle an der Medizinischen Hochschule Hannover
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Inclusion criteria (PROVID-CAPNETZ):
• Age = 18
• Radiological proof of infiltrate (primarily chest x-ray or CT) with positive detection of SARS-CoV-2-virus
or
• with no proven infiltrate with positive detection of SARS-CoV-2-virus
• Informed consent signed
Exclusion Criteria
Exclusion criteria (PROVID-CAPNETZ):
• Newly diagnosed, active pulmonary tuberculosis within the last 2 months
• Simultaneous participation in PROVID-PROGRESS or PROVID-CAPSyS cohort
• Participation of the patient in PROVID-PROGRESS or PROVID-CAPSyS cohort at an earlier point in time
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Aims:<br>Characterize the host- and virusdependent mechanisms associated with the clinical appearance of COVID-19 to improve patient care through advances in risk stratification and clinical management.<br>
- Secondary Outcome Measures
Name Time Method Aims:<br>Checking the following hypotheses:<br>1) Host factors (transcriptional response/RNA, proteins, antibodies) determine the severity and / or course of COVID-19.<br>2) Molecular and clinical determinants of COVID-19 differ from those that have been deciphered in other forms of pneumonia and they can be used as molecular predictors of disease progression.<br>3) Specific molecular markers of severe disease can be tested as therapeutic targets for COVID-19.<br>4) In addition to presently pursued antivirals and immunomodulators, the stabilization of the pulmonary barrier function could establish a third line for an effective therapy.<br><br>